Table 3 Humoral and Cellular response against the mRNA BNT162b2 vaccine in adolescents with RD and controls
Controls n = 24 | Adolescents with RD n = 40 | P | ||||
|---|---|---|---|---|---|---|
IFN-γ (pg/mL, median, IQR) | 529 (288 – 935) | 398 (209 – 1025) | 0.78 | |||
IL-2 (pg/mL, median, IQR) | 636 (265 – 834) | 497 (339 – 611) | 0.22 | |||
SARS-CoV-2 IgG antibodies > 10 index (%) | 23/24 (96%) | 38/40 (95%) | ||||
Naive | COVID-19 recovered | p | Naive | COVID-19 recovered | p | |
IFN-γ (pg/mL, median, IQR) | 450 (229 – 708) | 859 (412 – 1452) | 0.017 | 278 (202 – 784) | 849 (342 – 1526) | 0.024 |
IL-2 (pg/mL, median, IQR) | 398 (255 – 571) | 592 (490 – 705) | 0.036 | 632 (255 – 794) | 675 (364 – 1048) | 0.28 |
Naïve controls (n = 15) | Naïve adolescents with RD (n = 23) | p | ||||
IFN-γ (pg/mL, median, IQR) | 450 (229 – 708) | 278 (202 – 784) | 0.55 | |||
IL-2 (pg/mL, median, IQR) | 398 (255 – 571) | 632 (255 – 794) | 0.23 | |||
Controls (n = 24) | Adolescents with RD (JIA + SLE) (n = 32) | |||||
IFN-γ (pg/mL, median, IQR) | 529 (288 – 935) | 451 (216 – 1022) | 0.89 | |||
IL-2 (pg/mL, median, IQR) | 636 (265 – 834) | 653 ( 361 – 814) | 0.13 | |||